Jun Wu

Prof. Jun Wu

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TSTing Sun
Ting Sun
MCMengyun Chen
Mengyun Chen
HSHuanhuan Shen
Huanhuan Shen
PYPing Yin
Ping Yin
LFLi Fan
Li Fan
JZJunfeng Zhang
Junfeng Zhang
Background: Dyslipidemia is one of independent risk factors for coronary atherosclerotic heart disease (CAHD). We determined whether the LDL/HDL ratio is better than LDL-C or HDL-C alone in predicting the severity of CAHD. Methods: We performed a retrospective study of 1351 patients with myocardial ischemia who underwent coronary angiography between January 2018 and December 2019 in Shanghai Ninth People’s Hospital. Spearman correlation analysis, logistic regression model, Cox proportional hazards model and multicollinearity were used to evaluate LDL/HDL ratio for predicting CAHD severity compared to LDL-C or HDL-C alone. Results: Higher LDL/HDL ratio was seen in CAHD patients than controls (2.94 ± 1.06 vs 2.36 ± 0.78, P < 0.05). LDL/HDL ratio was significantly associated with the severity of coronary vascular stenosis. The area under the ROC curve of LDL-C, HDL-C, LDL/HDL ratio used to predict CAHD are 0.574 (95% CI 0.547–0.600, P < 0.001), 0.625 (95% CI 0.598–0.651, P < 0.001), 0.668 (95% CI 0.639–0.697, P = 0.000), respectively. The cut-off value of LDL/HDL ratio is 2.517, and the sensitivity and specificity are 65% and 61%, respectively. LDL/HDL ratio was related to the prevalence of CAHD and the odds ratio (OR) was 2.39 [95% confidence interval (CI) 1.698–2.593, P = 0.00] in multicollinearity regression model. Conclusion: LDL/HDL ratio may become a better predictor of CAHD severity, compared to LDL-C or HDL-C.

13 November 2019 in Aging
Verified
Journal Article
Open access
YDYanhua Du
Yanhua Du
JLJun Lin
Jun Lin
RZRulin Zhang
Rulin Zhang
WYWanli Yang
Wanli Yang
HQHeng Quan
Heng Quan
JWJun Wu
Jun Wu
Globally, epithelial ovarian cancer (EOC) is the most common gynecological malignancy with poor prognosis. The expression and oncogenic roles of ubiquitin specific peptidase 5 (USP5) have been reported in several cancers except EOC. In the current study, USP5 amplification was highly prevalent in patients with EOC and associated with higher mRNA expression of USP5. USP5 amplification and overexpression was positively correlated with poor prognosis of patients of ovarian serous carcinomas. Disruption of USP5 profoundly repressed cell proliferation by inducing cell cycle G0/G1 phase arrest in ovarian cancer cells. Additionally, USP5 knockdown inhibited xenograft growth in nude mice. Knockdown of USP5 decreased histone deacetylase 2 (HDAC2) expression and increased p27 (an important cell cycle inhibitor) expression in vitro and in vivo. The promoting effects of USP5 overexpression on cell proliferation and cell cycle transition, as well as the inhibitory effects of USP5 overexpression on p27 expression were mediated by HDAC2. Moreover, USP5 interacted with HDAC2, and disruption of USP5 enhanced the ubiquitination of HDAC2. HDAC2 protein was positively correlated USP5 protein, and negatively correlated with p27 protein in ovarian serous carcinomas tissues. Collectively, our data suggest the oncogenic function of USP5 and the potential regulatory mechanisms in ovarian carcinogenesis.

10 May 2023 in Cancer Medicine
Verified
Journal Article
Open access
RZRan Zhao
Ran Zhao
DXDongge Xia
Dongge Xia
YCYingwei Chen
Yingwei Chen
ZKZhentian Kai
Zhentian Kai
FRFangying Ruan
Fangying Ruan
XWXueliang Wang
Xueliang Wang
Background: Conventional blood and stool tests are normally used for early screening of colorectal cancer (CRC) but the accuracy and efficiency remain to be improved. Recent findings suggest Fusobacterium nucleatum to be a biomarker for CRC. This study evaluated the role of F. nucleatum and developed CRC diagnostic models by combining F. nucleatum with fecal occult blood (FOB), transferrin (TRF), carcinoembryonic antigen (CEA), carbohydrate antigen 19‐9 (CA19‐9), gender, and age.Materials and Methods: Candidates including 71 healthy individuals and 59 CRC patients were recruited. Abundance of F. nucleatum in stool or tissue samples was measured by quantitative real‐time PCR. CEA, CA19‐9, TRF, and FOB were measured in parallel. These biomarkers together with genders and ages were the seven parameters used to develop CRC diagnostic models. Ten different machine learning algorithms were tested to achieve the best performance.Results: Fecal F. nucleatum abundance was found significantly higher in CRC group compared to healthy group (p = 0.0005). Among the CRC patients, F. nucleatum abundance in tumor tissue was significantly higher than that in paracancerous tissue (p = 0.0087). CRC diagnostic models using different parameters were generated based on Logistic Regression algorithm, which showed good performance. The area under the curve (AUC) score of fecal F. nucleatum as the single diagnostic biomarker was 0.68 while the accuracy was 0.56. The diagnostic performance was obviously improved with the highest AUC (0.93) and accuracy (0.87) achieved when using all the 7 clinical parameters. The combination F. nucleatum + FOB + gender + age had the second highest AUC (0.92) and accuracy (0.85). A more utilitarian model using F. nucleatum + FOB showed relatively high AUC at 0.86 and accuracy at 0.81.Conclusions: F. nucleatum is valuable for CRC diagnosis. Combination of different clinical parameters could significantly improve CRC diagnostic performance. The combination F. nucleatum + FOB + gender + age may be an effective and noninvasive method for clinical application.

1 May 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
HLHan Liu
Han Liu
QZQiuxiang Zhou
Qiuxiang Zhou
XXXiang Xu
Xiang Xu
YDYanhua Du
Yanhua Du
JWJun Wu
Jun Wu
Background: Although increasing evidence supports a vital role for assembly factor for spindle microtubules (ASPM) and trophinin-associated protein (TROAP) in the tumorigenesis of some cancers, no systematic pancancer analyses of ASPM and TROAP have been performed. Thus, we aimed to investigate the potential functions of ASPM and TROAP across 31 cancer types. Methods: Based on datasets from The Cancer Genome Atlas (TCGA), Human Protein Atlas (HPA), Gene-Cloud of Biotechnology Information (GCBI) and Gene Expression Omnibus (GEO), we employed an array of bioinformatics methods to explore the potential oncogenic roles of ASPM and TROAP. Results: ASPM and TROAP, which were highly expressed in most cancers and presented a strict positive correlation, led to a decreased life expectancy among cancer patients. ASPM and TROAP both regulated cell replication in the S&G2 phase of the cell cycle. Through a protein-protein interaction network (PPI) analysis of ASPM and TROAP, we found that cell division cycle 20 (CDC20) was regulated by TROAP and functioned upstream of ASPM. Thus, TROAP can regulate the role of ASPM in cancers. Conclusions: The ASPM and TROAP have a significant positive correlation and similar expression profiles, and promote tumor malignancy and development in the S&G2 phase of the cell cycle. Since ASPM is one of the downstream targets of TROAP, TROAP and especially ASPM may be potential tumor makers and promising targets for therapeutic strategy.

23 November 2023 in Heliyon
Verified
Journal Article
Open access
RZRulin Zhang
Rulin Zhang
RYRui Yang
Rui Yang
ZHZhuodeng Huang
Zhuodeng Huang
XXXiang Xu
Xiang Xu
SLSiang Lv
Siang Lv
JWJun Wu
Jun Wu
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy and the third highest contributor to cancer-associated deaths globally. Research has increasingly demonstrated a strong correlation between long noncoding RNAs (lncRNAs) and the incidence and progression of HCC. Nonetheless, the exact mechanism whereby the function of lncRNAs in HCC has not been elucidated. This study explored the pathological role of LINC00294 in HCC, as well as the modulatory mechanism involved. Based on the “The Cancer Genome Atlas (TCGA)” database and validation in HCC cell lines and tissues, the expression of LINC00294 was discovered to be upregulated in HCC tissues and correlated with tumor grade and the prognosis of patients with HCC. Functionally, LINC00294 stimulated the proliferation of HCC cells as well as the Warburg effect (aerobic glycolysis) to enhance progression of tumor in vivo. Mechanistically, METTL3/YTHDC1-mediated N6-methyladenosine (m6A) modification underwent a significant enrichment within LINC00294 and was shown to enhance its RNA stability. Moreover, LINC00294 promoted the interaction between YTHDC1 and HK2 and GLUT1 mRNA. Overall, our study illustrates the m6A modification-mediated epigenetic mechanism of LINC00294 expression and regulatory role in HK2and GLUT1 mRNA expression and indicate LINC00294 as a potential biomarker panel for prognostic prediction and treatment in HCC.

12 September 2024 in JHEP Reports
Verified
Journal Article
Open access
JLJiajun Li
Jiajun Li
CZChi Zhang
Chi Zhang
QZQingqing Zhou
Qingqing Zhou
QLQinqin Long
Qinqin Long
JCJiayi Chen
Jiayi Chen
HTHua Tian
Hua Tian
Dysregulation of one-carbon metabolism is considered an early hallmark of mitochondrial dysfunction and cancer metabolism. ALDH1L2 belongs to the aldehyde dehydrogenase family and plays an important role in tumor progression. However, little is known about the precise role and underlying mechanisms of ALDH1L2 in hepatocellular carcinoma (HCC). Immunohistochemistry, western blotting, and immunofluorescence staining were used to evaluate ALDH1L2 expression in HCC samples (n = 90) and cell lines (n = 9). A series of in vitro and in vivo assays were performed to explore the role and molecular mechanism of ALDH1L2 in HCC progression. ALDH1L2 upregulation is associated with poor prognosis in HCC (hazard ratio 1.923; 95% confidence interval 1.03–3.59; p = 0.04). ALDH1L2 promotes tumor cell proliferation and metastasis by activating NRF2/IL-6/STAT3 signaling. ALDH1L2 promotes mitochondrial respiration, increases ATP production and protects HCC cells from reactive oxygen species-induced cellular damage via NRF2 stabilization. NRF2 also directly binds to the ALDH1L2 promoter and increases ALDH1L2 transcription, thereby establishing a positive feedback loop to maintain the function of ALDH1L2. The interaction between tumor-associated macrophages and ALDH1L2-overexpressing HCC cells further promotes HCC progression. In addition, ALDH1L2 knockdown enhances the anti-HCC activity of the tyrosine kinase inhibitor sorafenib. These findings provide the first evidence indicating that ALDH1L2 is directly involved in tumor progression by interacting with tumor-associated macrophages through the Jak2/STAT3 signaling pathway and that ALDH1L2 may be a target molecule for HCC therapy. This research highlights that ALDH1L2 could serve as a predictive and prognostic marker in HCC. We found that a positive feedback loop between ALDH1L2 and NRF2 promotes HCC progression by activating the IL-6/Jak2/STAT3 signaling axis and tumor-associated macrophage polarization. In addition, we found that ALDH1L2 knockdown enhances the anti-HCC effect of sorafenib.